Compare Novartis AG (NVS) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Tyson Foods, Inc. — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Tyson Foods, Inc. trades at $56.65 (market cap $20.11B). The key difference: Novartis AG is far larger — about 14.8× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| NVS | TSN | |
|---|---|---|
Market Cap | $298.18B | $20.11B |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $68.75 |
52-Week Low | $119.31 | $50.72 |
Enterprise Value | $339.50B | $27.37B |
Dividend Yield | 3.02% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Tyson Foods (TSN) trades at $58.04, down 0.85% on the day, with a bearish technical signal and mixed earnings history. The company reported Q3 2026 EPS of $0.99, beating estimates, but revenue trends are pressured by beef segment losses. Valuation metrics show a P/E of 35.83 and P/S of 0.37, with a consensus analyst price target of $68.50. Recent news highlights debt tender offers and a maintained quarterly dividend of $0.51.
The outlook is cautious due to persistent beef margin challenges, though chicken and prepared foods provide stability. Investment appeal lies in the discounted valuation and dividend yield, but risks include volatile input costs and competitive pressures. Analyst sentiment is divided, with 50% buy ratings but bearish technical indicators suggesting near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
